Tweet
All,
As we continue to look for new treatments I will do my best to inform the community about any new treatments in the pipline.
P-321, so it is called, a product from a company called Parion Sciences. It is currently in Phase II of trials. Parion entered into agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults.
The volume of tears on the eyes is the result of a delicate balance between tear production and tear loss. The epithelial sodium channel on the surface of the eye, promotes the loss of tear volume through the regulation of sodium and water absorption. P-321 Ophthalmic Solution is a novel inhibitor of ENaC, which blocks the loss of tears through the absorptive pathway. In multiple pre-clinical models of dry eye, ENaC inhibitors have demonstrated the ability to essentially restore and maintain normal tear volume. Parion has completed a phase 1/2a clinical study in 53 patients with dry eye disease and is pursuing the next steps in the clinical development for this program.
As we continue to look for new treatments I will do my best to inform the community about any new treatments in the pipline.
P-321, so it is called, a product from a company called Parion Sciences. It is currently in Phase II of trials. Parion entered into agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults.
The volume of tears on the eyes is the result of a delicate balance between tear production and tear loss. The epithelial sodium channel on the surface of the eye, promotes the loss of tear volume through the regulation of sodium and water absorption. P-321 Ophthalmic Solution is a novel inhibitor of ENaC, which blocks the loss of tears through the absorptive pathway. In multiple pre-clinical models of dry eye, ENaC inhibitors have demonstrated the ability to essentially restore and maintain normal tear volume. Parion has completed a phase 1/2a clinical study in 53 patients with dry eye disease and is pursuing the next steps in the clinical development for this program.